Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Chlorpropamide

FDA-approved product (tablet, oral), marketed as Chlorpropamide, Diabinese, Glucamide.

Registered studies
6
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Chlorpropamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonylureas
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli24.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

6registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Chlorpropamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Chlorpropamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

    NCT03492580 · start 2018-02-22

    Registered record
    Registry ID
    NCT03492580
    Conditions
    Diabetes Mellitus, Type 2; Cardiovascular Diseases
    Interventions
    Canagliflozin; Empagliflozin; Dapagliflozin; Dipeptidyl Peptidase-4 (DPP-4) Inhibitors; Glucagon-like Peptide-1 (GLP-1) Agonist; Anti-hyperglycemic Agents (AHA); Thiazolidinediones (TZD); Sulfonylureas (SU); Insulin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-02-22
    Completion
    2018-06-25
    Enrolment
    714,582

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2; Cardiovascular Diseases
    InterventionCanagliflozin; Empagliflozin; Dapagliflozin; Dipeptidyl Peptidase-4 (DPP-4) Inhibitors +5 more
    PhaseNot recorded
    Registry statusCompleted

  • Incretin-based Drugs and the Risk of Heart Failure

    NCT02456428 · start 2014-03

    Registered record
    Registry ID
    NCT02456428
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    DPP-4 inhibitors; GLP-1 analogs; Insulins; Biguanides; Sulfonylureas; Thiazolidinediones; Alpha-glucosidase inhibitors; Meglitinides
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-03
    Completion
    2015-05
    Enrolment
    1,499,650

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionDPP-4 inhibitors; GLP-1 analogs; Insulins; Biguanides +4 more
    PhaseNot recorded
    Registry statusCompleted

  • Incretin-based Drugs and Pancreatic Cancer

    NCT02475499 · start 2014-03

    Registered record
    Registry ID
    NCT02475499
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    DPP-4 inhibitors; GLP-1 analogs; Sulfonylureas; Biguanides; Thiazolidinediones; Alpha-glucosidase inhibitors; Meglitinides
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-03
    Completion
    2015-04
    Enrolment
    886,172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionDPP-4 inhibitors; GLP-1 analogs; Sulfonylureas; Biguanides +3 more
    PhaseNot recorded
    Registry statusCompleted

  • Incretin-based Drugs and Acute Pancreatitis

    NCT02476760 · start 2014-03

    Registered record
    Registry ID
    NCT02476760
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    DPP-4 inhibitors; GLP-1 analogs; Insulins; Biguanides; Sulfonylureas; Thiazolidinediones; Alpha-glucosidase inhibitors; Meglitinides
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-03
    Completion
    2015-04
    Enrolment
    1,417,914

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionDPP-4 inhibitors; GLP-1 analogs; Insulins; Biguanides +4 more
    PhaseNot recorded
    Registry statusCompleted

  • To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

    NCT01068860 · start 2010-02

    Registered record
    Registry ID
    NCT01068860
    Conditions
    Type 2 Diabetes Mellitus; Impaired Glucose Tolerance
    Interventions
    Canakinumab 150 mg; Placebo to Canakinumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-02
    Completion
    2010-08
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Impaired Glucose Tolerance
    InterventionCanakinumab 150 mg; Placebo to Canakinumab
    PhasePhase 2
    Registry statusCompleted

  • Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus

    NCT00004363 · start 1995-12

    Registered record
    Registry ID
    NCT00004363
    Conditions
    Diabetes Insipidus; Diabetes Insipidus, Neurohypophyseal
    Interventions
    chlorpropamide; desmopressin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1995-12
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Insipidus; Diabetes Insipidus, Neurohypophyseal
    Interventionchlorpropamide; desmopressin
    PhaseNot recorded
    Registry statusCompleted